<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906113</url>
  </required_header>
  <id_info>
    <org_study_id>0058-09-HMO</org_study_id>
    <nct_id>NCT00906113</nct_id>
  </id_info>
  <brief_title>Intra-arterial Chemotherapy for Children With Retinoblastoma</brief_title>
  <official_title>Phase 1-2 Study of Injection of Melphalan Into the Ophthalmic Artery in Children With Retinoblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinoblastoma is a cancer of the eye that occurs exclusively in children. The treatment for
      retinoblastoma may include surgery, chemotherapy, radiation and local treatments to the eye
      such as freezing (cryotherapy) and local radiation (brachytherapy). In some cases, a child
      with retinoblastoma will have active cancer in a single remaining eye with useful vision. In
      such cases, it is sometimes necessary to remove this eye. In such cases, the injection of
      chemotherapy directly into the artery that supplies the eye and the tumor may lead to
      regression of the tumor without the need to remove the eye.

      This form of treatment was pioneered by a group in New York (Abramson et al). In this study
      the investigators will assess the efficacy and safety of the technique in a group of children
      with retinoblastoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Salvage of eye and vision</measure>
    <time_frame>Three years from intervention</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Retinoblastoma</condition>
  <arm_group>
    <arm_group_label>Intra-arterial melphalan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will be treated by injection of chemotherapy (melphalan) into the ophthalmic artery of an eye affected by retinoblastoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-arterial injection of melphalan</intervention_name>
    <description>Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses</description>
    <arm_group_label>Intra-arterial melphalan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Injection of melphalan into the ophthalmic artery</intervention_name>
    <description>Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma</description>
    <arm_group_label>Intra-arterial melphalan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with retinoblastoma in a single remaining eye with useful vision

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Weintraub, MD</last_name>
    <phone>972-2-6777408</phone>
    <email>michaelw@hadassah.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacob Pe'er, MD</last_name>
    <phone>972-26778431</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Weintraub, MD</last_name>
      <email>michaelw@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Michael Weintraub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>October 1, 2016</last_update_submitted>
  <last_update_submitted_qc>October 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>Michael Weintraub</investigator_full_name>
    <investigator_title>DIrector, Pediatric Hematology Oncology</investigator_title>
  </responsible_party>
  <keyword>Retinoblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinoblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

